Table 1.

Demographic, Clinical, and Laboratorial Information

	Survived (n = 22)	Died (n = 5)	P value
Age (mean)	60 (± 12)	56 (± 10)	0.75
≥60 years old (%)	12 (54.5)	2 (40)	0.64
Male (%)	17 (77.3)	4 (80)	0.89
Ethnicity (%)
White	19 (86.4)	4 (80)	(reference)
Asian	2 (9.1)	0 (0)	-
Black	1 (4.5)	1 (20)	0.30
COVID-19 wave (%)
First wave	4 (18.2)	3 (60)	0.91
Second wave	18 (81.8)	2 (40)
Comorbidities
Charlson Comorbidity Index (mean)	1.55 (± 1.18)	1.2 (± 1.10)	0.25
Hypertension (%)	10 (45.5)	2 (40)	0.61
Diabetes mellitus (%)	12 (54.5)	2 (40)	0.46
Obesity (%)	4 (18.2)	2 (40)	0.30
Chronic kidney disease (%)	5 (22.7)	0 (-)	0.32
Years from transplantation (mean)	6.3 (± 3.8)	3.4 (± 4.8)	0.22
Immunosuppressor Use at Admission (%)
Cyclosporine	5 (22.7)	0 (-)	-
Tacrolimus	13 (59.1)	4 (80)	0.62
Mycophenolate	13 (59.1)	3 (60)	0.684
Azathioprine	2 (9.1)	1 (20)	0.47
Steroids	0 (-)	0 (-)	0.23
Everolimus	7 (31)	2 (40)	0.53
Symptoms on Admission (%)
Fever	11 (50)	4 (80)	0.34
Cough	11 (50)	2 (40)	1.0
Dyspnea	3 (13.6)	2 (40)	0.22
Fatigue	5 (22.7)	2 (40)	0.58
Myalgia	9 (40.9)	1 (20)	0.62
Nausea or vomiting	1 (4.5)	1 (20)	0.34
Odynophagia	1 (4.5)	0 (-)	1.0
Abdominal pain	1 (4.5)	0 (-)	1.0
Laboratory Values at Admission
Lymphocyte count, cells/µL	1102 (± 616)	635 (± 177)	0.35
AST (UI/L)	48 (± 47)	84 (± 98)	0.43
ALT (UI/L)	43 (± 53)	93 (± 111)	0.34
C-reactive protein	96 (± 0)	167 (± 99)	0.59
Hospitalization (%)	12 (54.5)	5 (100)	0.47
ICU admission (%)	0 (-)	5 (100)	< 0.001
Intubation (%)	0 (-)	5 (100)	< 0.001
Immunosuppressive Regimen Modifications (%)
Partial or total suspension	8 (33.6)	5 (100)	0.039
Suspension of tacrolimus (either alone or with other drugs)	3 (75)	1 (25)	0.006

ALT, alanine aminotransferase; AST, aspartate aminotransferase; ICU, intensive care unit.